Journal
EVALUATION AND PROGRAM PLANNING
Volume 34, Issue 4, Pages 375-381Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.evalprogplan.2011.02.004
Keywords
Medication-assisted treatment; Treatment of substance use disorders; Barriers to implementation
Categories
Funding
- NIAAA NIH HHS [F32 AA016872-03, F32AA016872, F32 AA016872] Funding Source: Medline
- NIDA NIH HHS [K01 DA021309, R01 DA014482, K01 DA021309-02, R01 DA014482-03, K01DA021309, R01DA014482, R01 DA014482-04, R01 DA014482-05] Funding Source: Medline
Ask authors/readers for more resources
Despite growing interest in the use of evidence-based treatment practices, adoption of pharmacotherapies for treating substance use disorders (SUDs) remains modest. Using data from telephone interviews with 250 administrators of publicly funded SUD treatment programs, this study estimated a model of adoption of medication assisted treatment (MAT) for SUDs and examined the relative importance of regulatory, cultural, medical resource, patient-level, and funding barriers to MAT implementation. MAT-adopting programs had significantly greater medical resources, as measured by the employment of physicians and nurses, than non-adopting programs. Administrators of non-adopting programs were asked to rate the importance of 18 barriers to MAT implementation. The most strongly endorsed barriers were regulatory prohibitions due to the program's lack of medical staff, funding barriers to implementing MAT, and lack of access to medical personnel with expertise in delivering MAT. Barriers related to insufficient information about MAT and unsupportive staff attitudes were not widely endorsed. These findings suggest that efforts to promote the implementation of MAT that are inattentive to funding barriers and weaknesses in medical infrastructure may achieve sub-optimal results. (C) 2011 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available